Trial · NCT07398404
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Study enrollment to assess Feasibility | 16 weeks | Number of participants enrolled out of participants screened. |
| Primary | Mean number treatment sessions attended to assess Feasibility | 16 weeks | Mean number of treatment sessions attended. |
| Primary | Retention to assess Feasibility | 16 weeks | Retention will be measured as the percent of participants that attend the post treatment assessment. |
| Primary | Treatment credibility to assess Acceptability | Week 4, Week 8, Week 12, Week 16 | Treatment credibility will be assessed via self-report monthly. Acceptability measured as the percent of participants that agree the intervention is acceptable (0-100%, with higher scores being indicative of higher treatment credibility). |
| Primary | Treatment satisfaction to assess Acceptability | Week 16 | Treatment satisfaction will be assessed via self-report at post-treatment. Acceptability measured as the percent of participants that agree the intervention is satisfactory (0-100%, with higher scores being indicative of higher treatment satisfaction). |
| Primary | Percent weight change | Baseline, Week 16, 6-month follow-up | Percent weight change will be calculated from baseline to post-treatment, and post-treatment to 6-month follow-up. |
| Primary | Smoking cessation, as measured by exhaled carbon monoxide | Baseline, Week 4, Week 8, Week 12, Week 16, 6-month follow-up | Smoking cessation will be evaluated biochemically, through mean exhaled carbon monoxide concentration. |
| Primary | Smoking cessation, as measured by timeline followback interview | Baseline, Week 4, Week 8, Week 12, Week 16, 6-month follow-up | Smoking cessation will be evaluated behaviorally, through point prevalence abstinence data obtained by timeline followback interviews. |
| Secondary | Nicotine dependence, as measured by the Fagerstrom Test for Nicotine Dependence | Baseline, Week 16, 6-month follow-up | The Fagerstrom Test for Nicotine Dependence is a self-report measure that classifies level of nicotine dependence. Participants respond to a series of questions assessing time of first cigarette after waking, difficulty refraining from smoking in places where smoking is prohibited, and frequency of smoking. Total score range 0-10 with higher scores indication more nicotine dependence. |
| Secondary | Depressive symptomatology, as measured by the Patient Health Questionnaire-9 | Baseline, Week 16, 6-month follow-up | The Patient Health Questionnaire-9 is a brief, psychometrically sound, and widely used self-report measure of depression in diverse medical settings. The total score on the PHQ-9 ranges from 0 to 27, with higher scores indicating greater severity of depressive symptoms. |
| Secondary | Physical activity, as measured by the Global Physical Activity Questionnaire (GPAQ) | Baseline, Week 16, 6-month follow-up | GPAQ is a validated self-report assessment of physical activity and sedentary behavior. GPAQ does not have a single fixed total score range but a score is calculated in METs-minutes per day. Participants are classified as "active" if they meet or exceed 600 METs-minutes per week. |
| Secondary | Number of participants with Bariatric surgery completion | 6-month follow-up | Bariatric surgery completion will be assessed at 6-month follow-up, through medical record review. |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07398404/registered